|
KMID : 1007320080140010001
|
|
Journal of the Korean Society of Menopause
2008 Volume.14 No. 1 p.1 ~ p.8
|
|
|
Pharmacological Characteristics of Drospirenone
|
|
Yi Kyong-Wook
Hur Jun-Young
|
|
|
Abstract
|
|
|
|
In postmenopausal women, hormone therapy (HT) relives the part of postmenopausal symptoms, such as vasomotor symptoms (hot flushes, palpitation), psychological well-being, and osteoporosis. As with estrogens, the various progestogens used in HT for protection of the endometrium may differ as to their pharmacological properties. Drospirenone (DRSP) is an analogue to spironolactone, aldosterone antagonist, and is unique progestogen. The pharmacological profile of DRSP resembles that of the natural progesterone, especially with regard to anti-mineralocorticoid and anti-aldosterone activities. Recent clinical trials have been confirmed that DRSP/estradiol combination provides effective relief of menopausal symptoms, such as hot flushes, genitourinary atropy, and improves bone mineral density; thus reducing the risk of osteoporosis. In addition, the anti-aldosterone activityof DRSP counteracts sodium and water retention contributes to the maintenance of stable body weight, and has potential benefits for blood pressure in postmenopausal women. The DRSP/estradiol combination offers a new choice beyond the effective management of menopausal symptoms, with additional favorable effects due to its anti-aldosterone properties.
|
|
|
KEYWORD
|
|
|
Drospirenone, Hormone therapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|